B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma

• Published in: ESC heart failure 2024, Vol.11 (1), p.574-580
• Main Authors: Wang, Yunhong, Zhang, Ke, Suo, Xiaohui, Meng, Ning, Gu, Yuanrui, Qin, Yilang, Tu, Yanxia, Zhang, Xiaohui, Sun, Guofeng, Ji, Jiaojiao, Wu, Weichun, Cai, Yuqi, Yang, Kai, Ouyang, Chenxi, Qi, Junyuan
• Format: Report
• Language: English
• ISSN: 2055-5822
• DOI: 10.1002/ehf2.14554

Patients with multiple myeloma (MM) are likely to achieve poor therapeutic response when organs are involved. We produced anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells, which are in a trial for patients with relapsed/refractory MM. One enrolled patient developed severe heart failure, highly suspected as light chain cardiac amyloidosis. He exhibited increased N-terminal pro-brain natriuretic peptide with a peak of 32 299 ng/mL and heart failure with an ejection fraction of 30%. Anti-BCMA CAR-T cells were administered following lymphodepletion. The patient achieved cardiac response within 1 week with a decrease in N-terminal pro-brain natriuretic peptide by 80%, an increase in ejection fraction from 30% to 56%, and a haematological response with negative minimal residual disease at 1 month and a complete response at 1 year. To date, this patient has maintained good health without heart failure or haematological relapse. Herein, we show the efficacy of anti-BCMA CAR-T cells in patients with MM and severe heart failure.